For more information please contact email@example.com or 800-936-9669.Forward Looking Statements To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of Fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for Fexapotide. Such forward looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox's regulatory filings, Nymox's substantial dependence on Fexapotide, Nymox's commercialization plans and efforts and other matters that could affect the availability or commercial potential of Fexapotide. Nymox undertakes no obligation to update or revise any forward looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2016, and its Quarterly Reports. Contact:Paul AverbackNymox Pharmaceutical Corporation800-93NYMOX www.nymox.com
HASBROUCK HEIGHTS, N.J., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that an important large symposium and panel assessment of the Company's new drug Fexapotide Triflutate will be held at the October meeting of the American Urological Association, South Central Section. The October 5 symposium at the AUA meeting will include new data presentations from prominent Fexapotide clinical trial urologists, and will feature panel assessments and discussion of results from the U.S. Fexapotide trials undertaken in 2009-2017. The Chairperson of the Symposium will be Mohammed Bidair MD of San Diego Clinical Trials, San Diego, CA. Further details on the October Symposium at the AUA Meeting will be provided prior to the meeting. Dr. Paul Averback, CEO of Nymox said, "The upcoming Symposium at the AUA meeting next month will involve highly experienced BPH investigators who participated in the trials and who will present data and discuss results of the Fexapotide Phase 3 clinical studies. Although unavoidably the earlier Mid-Atlantic September meeting was postponed due to emergency hurricane conditions, we are very pleased that the October meeting will soon occur. Our management is highly committed to communication activities which are being actively generated with the medical communities. This will be the first of many important undertakings which will occur." Nymox's lead drug Fexapotide has been in development for over 10 years and has been tested by expert clinical trial investigative teams in over 70 distinguished clinical trial centers throughout the US, and has been found after 7 years of prospective placebo controlled double blind studies of treatment of 995 U.S. men with prostate enlargement to not only show clinically meaningful and durable relief of BPH symptoms, but also to show a major reduction in the incidence of prostate cancer, compared to placebo and compared to the known and expected normal incidence of the disease. The same clinical program has also shown in a long-term blinded placebo crossover group study an 82-95% reduction in the number of these patients who required surgery after they received crossover Fexapotide in the trial, as compared to patients who did not receive Fexapotide but instead received crossover conventional approved BPH treatments (p<.0001).